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willing to lower the prices to the requested level, on condition that the price will not 
appear on any kind of ofﬁcial price list, to prevent “reverse referencing” to the prices 
in other bigger markets in the EU. Even though unsuccessful, these attempts may 
indicate that the pharmaceutical sector will continue to make their pricing as secretive 
as possible.
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ORGANIZATION: This joint presentation of the Netherlands Organization for 
Health Research and Development and the Netherlands Healthcare Insurance Board 
will introduce the support structures for HTA in the country and its use when deciding 
on the composition of the insurance package. PROBLEM OR ISSUE ADDRESSED 
AND GOALS: Design and results of the Health Care Efﬁciency Research Program 
including early evaluation, effects and costs, implementation and high costs /orphan 
drugs research will be presented. The role of the Board in safeguarding and developing 
public preconditions for the health care insurance system will be delineated. Focusing 
on insurance package management, selection and prioritization of the topics will be 
explained. Processes in place for collection of HTA information, including coordina-
tion between research and package agenda as well as use of national and international 
methodology and results are discussed. OUTCOMES ITEMS USED IN THE DECI-
SION: Through presentation of selected diseases / conditions and their treatments the 
pathway from research to package decision will be highlighted. In addition, the role 
of the advisory committees of the Board, including pharmaceutical, package clariﬁca-
tion and package advise are explained. And the relation between the Insurance Board, 
the Health Care Efﬁciency Research Program and the Ministry of Health will be clari-
ﬁed. Furthermore, the conditions needed to optimize the assessment—appraisal inter-
play are described and critically evaluated. HTA information is not considered relevant 
only for the package decisions and advise to the MOH. IMPLEMENTATION 
STRATEGY: Other parties in the health system, including providers, insurers and 
patients are also increasingly making use of it. Ways and means of making the infor-
mation, from the two organizations, accessible and understandable for other users will 
be presented. RESULTS AND LESSONS LEARNED: Finally, internationalization of 
the research methodology and results will be reviewed, as well as use of this knowledge 
in the Netherlands.
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REQUIREMENTS FOR LATER LINES OF TREATMENT WILL INCREASE 
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OBJECTIVES: This analysis investigates the implicit cost-effectiveness requirements 
for new therapies used earlier in a treatment sequence when cost-effectiveness thresh-
olds have been relaxed for for later lines of therapies. Two examples of this are: 1) 
The National Institute for Health and Clinical Excellence (NICE) decision to allow 
higher cost-effectiveness thresholds for later lines of therapy in certain oncology indi-
cations, and 2) The Swedish Dental and Pharmaceutical Beneﬁts Board (TLV) implicit 
decisions to accept higher thresholds with later line restrictions. METHODS: A simple 
example is constructed where a new competing 1st line therapy (A) can replace the 
currently used therapy (B). It is assumed that if no further lines of therapy exists then 
therapy A would be considered cost-effective compared to B using a formal threshold 
level of T. A third therapy (C) is approved to be used only in 2nd line therapy and is 
accepted at a higher cost-effectiveness threshold than T. The problem is focused on 
the formal evaluation of the incremental cost-effectiveness ratio of the new therapy A 
vs. B in the presence of therapy C. RESULTS: The implication of relaxing the cost-
effectiveness requirement for later lines of therapies is a further strengthening of the 
requirement of new therapies for earlier use in treatment sequences. In the most 
extreme scenario a new therapy, with less cost and higher effectiveness compared to 
standard therapy in a speciﬁc line, may not be considered cost-effective. CONCLU-
SIONS: This increased implicit cost-effectiveness threshold by the new regulations may 
risk crowding-out of new cost-effective therapies in earlier lines unless the explicit 
requirements/thresholds are modiﬁed using the highest accepted ratio between the 
costs and efﬁcacy in the treatment sequence. Another solution is to evaluate and 
compare complete treatment sequences.
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OBJECTIVES: Limited use of economic evaluation in decision-making may in part 
reﬂect neglect of equity concerns. We reviewed published studies describing formal 
methods to integrate equity into cost-effectiveness and cost-utility analyses (CEA). 
METHODS: Candidate articles were identiﬁed via a search of Pub Med and EMBASE 
databases without language or date restrictions, and hand-searching of article bibli-
ographies. All original research articles, reviews, commentaries or editorials describing 
formal methods to integrate equity into CEA were candidates for inclusion. To select 
studies, candidate titles, abstracts and full text articles were reviewed independently 
by each author. Review was not blinded. Authors jointly determined study inclusion 
on the basis of individual assessments and discussion. Disagreements of opinion were 
resolved by consensus. Articles were excluded if they met one or more of the following 
criteria: not about CEA, not about equity, not a formal proposal, not an original 
proposal, proposal lacking in speciﬁcity. To facilitate narrative synthesis, articles were 
classiﬁed into families of approaches based on consensus groupings established jointly 
by the authors. RESULTS: The search identiﬁed 679 potentially relevant studies, of 
which 93 were retrieved for detailed (full text) evaluation following a review of titles 
and abstracts. After full-text screening an additional 47 studies were excluded, yielding 
46 studies for review. Studies were classiﬁed into the following approaches to equity: 
equity weighting by age (n  8), gender (n  1) or disease severity (n  7); social welfare 
function approaches (n  10); mathematical programming (n  8); dispersion and 
concentration of health beneﬁts (n  3); proportionalism (n  4); and multicriteria 
proposals (n  5). Most (n  40) described theoretical proposals. CONCLUSIONS: 
There exists a wide variety of formal methods to incorporate equity into CEA; 
however, their potential has not been fully exploited. To enhance viability and uptake, 
speciﬁc recommendations are made for further methodological development and 
increased links with normative theory.
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OBJECTIVES: We report the ﬁndings of a discrete choice experiment (DCE) undertaken 
to evaluate the consistency of public and decision-maker preferences for the public 
subsidy of pharmaceuticals. METHODS: The DCE compares the relative importance 
of gains in survival, quality of life (QoL), chance of response success and government 
costs in pharmaceutical funding decisions, and the impact that the initial severity of 
illness has on preferences. The DCE was administered to a sample of the Australian 
public and members of the Australian Pharmaceutical Beneﬁts Advisory Committee 
(PBAC) and its Economic subcommittee. A mixed logit model was employed for data 
analysis. RESULTS: For both samples, an increased survival, QoL or chance of response 
success, or a reduction in cost or uncertainty (decision-makers only), increased the 
likelihood that a pharmaceutical would be chosen for funding. Further, both samples 
were more likely to fund a pharmaceutical which was used for the treatment of severe 
illness. Considerable preference heterogeneity was observed for both samples. CON-
CLUSIONS: While there is consistency between attributes the public are willing for 
the government to pay more when compared with the decision makers who understand 
the budget restrictions on decisions. Overall, this novel study suggests a high level of 
agreement between public and decision-makers in the trade-offs they are willing to 
make when new pharmaceuticals are considered for public subsidy.
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OBJECTIVES: To test and further develop a decision support framework (EVIDEM) 
using growth hormone (GH) for Turner syndrome (TS) as a complex case study. 
METHODS: The MCDA matrix included 15 quantiﬁable components of decision 
clustered in four domains (quality of evidence, disease, intervention and economics). 
Six non-quantiﬁable components of decision were identiﬁed and organized into a tool 
using an ethical framework. A synthesized health technology assessment (HTA) report 
on GH for TS tailored to each component of decision was prepared and validated by 
experts. A panel of representative stakeholders estimated the MCDA value of GH for 
TS in Canada by assigning weights and scores. Impact of non-quantiﬁable components 
of decision was also considered. Validity of approach was explored. RESULTS: The 
HTA report revealed data needs for decisionmaking in particular regarding patient 
reported outcomes. Panelists estimated the value of GH for TS at 41% (min: 26%, 
max: 54%) of maximum value on the MCDA scale. Retest value estimate was 40% 
with high intra-rater agreement. Main contributors to value estimate were quality of 
evidence, disease severity, improvement of clinical and patient reported outcomes 
compared to no treatment. Signiﬁcant expenditures associated with GH contributed 
little to value. Ethical considerations had mixed effects on value of GH. On average, 
71% of panelists indicated that the same 13 quantiﬁable and 4 non-quantiﬁable 
components should always be considered. CONCLUSIONS: The framework allows 
transparent consideration of all components of decision and underlying evidence. 
Further testing and validation is needed to further develop MCDA approaches in 
health care decisionmaking.
